Podcasts about blinatumomab

Dr. Yuz Yusof reports on abstract OP0193, presented at Eular 2024 in Vienna, Austria.

En Londres, algunos niños con leucemia en 20 centros médicos están recibiendo un nuevo tipo de tratamiento farmacológico que es menos tóxico y no debilita tanto como la quimioterapia.See omnystudio.com/listener for privacy information.

In einer internationalen Studie haben deutlich mehr erkrankte Babys die ersten beiden Jahre nach der Diagnose akute lymphatische Leukämie überlebt. Sie erhielten zusätzlich zur Chemotherapie eine Immuntherapie mit Blinatumomab. Von Daily Good News.

Blinatumomab - it's Oprah's new favorite drug! On this episode, Anthony and Bernie are joined by special guests Dr. Lydia Benitez and Dr. Patrick Burke to discuss the ECOG1910 trial of blinatumomab in adult ALL. Is this trial practice changing? Listen and find out! ECOG1910 Late-Breaking Abstract: https://ash.confex.com/ash/2022/webprogram/Paper171751.html

Key papers discussed in the show: 1.     Pediatric regimen for older adolescents and young adults with ALL: CALGB 10403 https://ashpublications.org/blood/article/133/14/1548/260519/A-pediatric-regimen-for-older-adolescents-and2.     Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: C19802 https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.276173.     Rituximab in B-ALL https://www.nejm.org/doi/full/10.1056/NEJMoa16050854.     A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients with Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia: SWOG 1318 https://ascopubs.org/doi/abs/10.1200/JCO.21.017665.     Blinatumomab for MRD in adults with B-ALL https://ashpublications.org/blood/article/131/14/1522/36655/Blinatumomab-for-minimal-residual-disease-in6.     Ph-like ALL https://www.nejm.org/doi/10.1056/NEJMoa1403088

In this episode, Julie M. Vose, MD, MBA;  Brad S. Kahl, MD; and  John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on: Follicular lymphomaMarginal zone lymphomaMantle cell lymphomaDiffuse large B-cell lymphomaPosttransplant lymphoproliferative disorderPresenters:Julie M. Vose, MD, MBAChief, Division of Oncology and HematologyNeumann M. and Mildred E. Harris ProfessorDepartment of Internal MedicineUniversity of Nebraska Medical CenterOmaha, NebraskaBrad S. Kahl, MDProfessor of MedicineDepartment of Medical OncologyWashington University School of MedicineSt Louis, MissouriJohn P. Leonard, MDRichard T. Silver Distinguished Professor of Hematology and Medical OncologyProfessor of MedicineWeill Cornell MedicineNew York Presbyterian HospitalNew York, New YorkLink to the complete program, including downloadable slidesets, expert commentaries, an on-demand webcast, and treatment resource guides:https://bit.ly/3tb47wU

La Dra. Martha Alvarado Ibarra, hematólogo, jefa del Departamento de Hematología del CMN "20 de Noviembre", ISSSTE, tiene como invitada especial en este episodio de "Charla hematológica" a la Dra. Luara Luz Arana Luna, hematólogo adscrita a la misma institución, ambas de la Ciudad de México, México, para comentar lo más destacado sobre leucemia linfoblástica aguda, presentado en EHA2021. Dentro de su conversación, las expertas resuelven las siguientes interrogantes: ¿Cuál es su opinión en relación con aquellos protocolos pediátricos que planean medir la enfermedad mínima residual a la mitad de la inducción? ¿Blinatumomab sustituirá al trasplante en algún momento? Se presentó el estudio EWALL-BOLD a propósito de la experiencia con blinatumomab en personas mayores de 66 años, ¿Qué se puede rescatar de ese trabajo? Entre otras…

Editor's Summary by Mary McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the March 2, 2021 issue

In this episode, David Marks, MD, PhD, and Stéphane de Botton, MD, answer questions from clinicians on management pearls for patients with acute leukemias. Topics include:MRD in the management of ALLTherapy choice for older patients with AMLOptimal use of inotuzumab ozogamicin and blinatumomab for ALLUse of CAR T-cell therapy for acute leukemiasContent based on an online CME program supported by an educational grant from Pfizer Inc.Link to full program:https://bit.ly/3jiCBaD

HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.   These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.   In this episode of HOPA Now, Dr. Bernard Marini highlights the main clinical pearls of adult acute leukemias and myelodysplastic syndrome, including unique factors that affect dosing, drug monitoring factors, and guidelines, and the oncologic stewardship and dosing caps for various drug usage.   In this episode you will learn:   Adult Acute Leukemias & Myelodysplastic Syndrome: Top 10 Clinical Pearls There are unique lenalidomide sensitivities for patients with deletion 5q. Thrombopoietin mimetics and growth factors for patients with MDS Guidelines for use of potent ASAL antifungals Denosumab azomycin and oncologic stewardship and dosing caps Secondary AML and oncologic stewardship outcomes and alternatives Characteristics and management of IDH inhibitors and differentiation syndrome Asparaginase and therapeutic drug monitoring and a comparison of adult versus pediatric patients reactions and survival rates Blinatumomab and inotuzumab use and outcomes in patients with less disease burden Balancing safety and efficacy of TKIs in patients with ph positive ALL   Mentioned in This Episode: HOPA   Quotes:   “Patients with deletion 5q are uniquely sensitive to lenalidomide.” — Dr. Bernard Marini   “Given the flaws in the alpha trial and the meta-analysis, this is potentially a place for oncologic stewardship in avoidance in risk in a drug with no overall survival benefit.” — Dr. Bernard Marini   “IDH inhibitors in AML are fascinating agents.” — Dr. Bernard Marini   “Adults and young adult patients have significantly worse survival rates compared to pediatric ALL counterparts.” — Dr. Bernard Marini  

Alex Ganetsky, PharmD, BCOP, oncology clinical pharmacy specialist at the Hospital of the University of Pennsylvania in Philadelphia discusses the approval to blinatumomab (Blincyto, Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

Dr Gökbuget talks to ecancertv at ASH 2015 about the long-term outcomes of patients with minimal residual disease positive (MRD ) B-cell precursor acute lymphoblastic leukaemia (ALL). Specifically, she highlights the findings of an international, multicentre phase II study in MRD ALL in which approximately 80% of patients achieved a complete MRD response, with no detectable disease after just 4 weeks of treatment with blinatumomab. The median overall survival was 36 months, which is a big improvement, and the median remission duration and relapse-free survival was 18 months and more, Dr Gökbuget says. The results suggest that treating MRD ALL before patient relapse can have a big effect on long term outcomes and that all clinicians should measure MRD, she suggests.

Prof Martinelli talks to ecancertv at ASH 2015 about the effects of the tyrosine kinase inhibitor blinatumomab in patients with Philadelphia-positive (Ph ), B-cell precursor acute lymphoblastic leukaemia (ALL) who had relapsed or who were not responding to their current treatment regimen. This is a very rare population of patients in a very rare disease, Prof Martinelli observes, which is important because there are few options once treatment with tyrosine kinase inhibitor therapy fails and the prognosis of patients is rather dismal. Results from the Phase II, single-arm, multicentre ALCANTARA study, however, suggest there could be a benefit of using the bispecific T-cell engaging (BiTE®) antibody construct blinatumomab.

Dr Topp talks to ecancer at EHA 2017 about a randomised phase 3 trial that compares blinatumomab, a bispecific T-cell engager antibody construct and standard of care (SOC) chemotherapy in patients with Philadelphia chromosome−negative relapsed/refractory B-precursor acute lymphoblastic leukaemia. Blinatumomab showed improved overall survival rates in the study, which Dr Topp discussed with ecancer at EHA 2016, and here Dr Topp discusses here how the toxicity profile is consistent with that previously reported for relapsed/refractory acute lymphoblastic leukaemia, including manageable CRS and neurologic events.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: AIFA, EMA, Aristo Pharma, QuintilesIMS, PSI CRO, INC Research, Chiltern, Parexel, ICON, PPD, Amgen, PTC Therapeutics.Persone: Giuseppe Sala (Sindaco di Milano), Giorgio Foresti (Aristo Pharma), Filippo Boschetti (QuintilesIMS), Marcello D’Amelio (Università Campus Bio-Medico di Roma), Glenis Willmott (Parlamento Europeo), Eugenio Mercuri (Università Cattolica di Roma), Manuela Maronati (PTC Therapeutics).Nuove terapie: Blinatumomab, Ataluren.Patologie: depressione, Alzheimer, leucemia linfoblastica acuta, distrofia di Duchenne.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: AIFA, EMA, Aristo Pharma, QuintilesIMS, PSI CRO, INC Research, Chiltern, Parexel, ICON, PPD, Amgen, PTC Therapeutics.Persone: Giuseppe Sala (Sindaco di Milano), Giorgio Foresti (Aristo Pharma), Filippo Boschetti (QuintilesIMS), Marcello D’Amelio (Università Campus Bio-Medico di Roma), Glenis Willmott (Parlamento Europeo), Eugenio Mercuri (Università Cattolica di Roma), Manuela Maronati (PTC Therapeutics).Nuove terapie: Blinatumomab, Ataluren.Patologie: depressione, Alzheimer, leucemia linfoblastica acuta, distrofia di Duchenne.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

Prof Topp presents, at a press conference at EHA 2016, the results of a single arm Phase II trials with blinatumomab which have shown that 43% of relapsed or refractory (r/r) ALL patients can achieve disease control.

Prof Topp talks to ecancertv at EHA 2016 about blinatumomab to treat relapsed or refractory B-cell acute lymphoblastic leukaemia (rrALL). With results from the phase III TOWER study, he reports on media overall survival being almost doubled with blinatumomab compared to standard care, and that previous neurologic side effects associated with blinatumomab are found to be equal to those in patients receiving comparable chemotherapy, and with reduced risk of cytokine syndrome than CAR T-cell therapy.

Prof Max Topp ( Würzburg University Hospital, Würzburg, Germany) talks to ecancertv at EHA 2015 about his research which showed that acute lymphoblastic leukaemia (ALL) patients with low disease burden had lower responses to blinatumomab. Those with higher disease burden could be candidates for higher doses of blinatumomab or cytoreduction. ecancer's filming at EHA has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor acute lymphoblastic leukemia (ALL). However, about half of relapsed/refractory patients do not respond to therapy. Here, we present the case of a 32-year-old male patient with refractory B-precursor ALL who was resistant to treatment with blinatumomab. Bone marrow immunohistochemistry revealed T cell infiltrates and an increase in programmed death-ligand 1 (PD-L1)-positive ALL cells as a potential immune escape mechanism. We were able to recapitulate the clinical observation in vitro by showing that blinatumomab was not able to mediate cytotoxicity of CD19-positive ALL cells using autologous T cells. In contrast, the addition of healthy donor T cells led to lysis of ALL cells. These results strongly encourage further systematic evaluation of checkpoint molecules in cases of blinatumomab treatment failure and might highlight a possible mechanism to overcome resistance to this otherwise highly effective treatment.

Today in FirstWord:

Today in FirstWord: